Product Information
KAITLIB FE 0.8-0.025 MG CHEW TB is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $1.4035 per EA under NDC 68180090373. Its NADAC has been published 282 times since May 12, 2021.
FDA first approved this application on Dec 17, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180090373
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA203448FDA Approved
12/17/2015
TE Code
AB
On Market Since
2/7/2021
Price Statistics
The NADAC for KAITLIB FE 0.8-0.025 MG CHEW TB has been published 282 times since May 12, 2021, and over the history we have for it it has declined 37.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4035 per EA |
|---|---|
| All-time high | $2.6953 (Oct 13, 2021) |
| All-time low | $0.9745 (Feb 21, 2024) |
| 52-week high | $1.8790 |
| 52-week low | $1.2570 |
| Median price | $1.7211 |
| Average price | $1.6610 |
| Largest weekly change | +54.1% (Sep 22, 2021) |
| Weeks tracked | 282 |
| Tracking since | May 12, 2021 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 86% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KAITLIB FE 0.8-0.025 MG CHEW TB?
The current National Average Drug Acquisition Cost (NADAC) for KAITLIB FE 0.8-0.025 MG CHEW TB, manufactured by Lupin Pharmaceuticals Inc., is $1.4035 per EA (NDC 68180090373), effective Sep 30, 2026.
How has the price of KAITLIB FE 0.8-0.025 MG CHEW TB changed over time?
Over the history we have for it, the NADAC for KAITLIB FE 0.8-0.025 MG CHEW TB has declined 37.6%. It has been tracked across 282 weekly CMS publications since May 12, 2021.
What are the highest and lowest recorded NADAC prices for KAITLIB FE 0.8-0.025 MG CHEW TB?
Since May 12, 2021, the NADAC for KAITLIB FE 0.8-0.025 MG CHEW TB has ranged from a low of $0.9745 (Feb 21, 2024) to a high of $2.6953 (Oct 13, 2021), with a median of $1.7211 per EA.
Are there cheaper alternatives to KAITLIB FE 0.8-0.025 MG CHEW TB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ALYACEN 1-35 28 TABLET, is $0.2026 per EA — about 86% below KAITLIB FE 0.8-0.025 MG CHEW TB.
Who manufactures KAITLIB FE 0.8-0.025 MG CHEW TB?
KAITLIB FE 0.8-0.025 MG CHEW TB (NDC 68180090373) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.